EcoDrugPlus

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSSMAG00000014621
Gene Symbol: FLT1
1 Cross references
198 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSSMAG00000007017
Gene Symbol: FLT4
1 Cross references
193 Possible Orthologues:

Focal Adhesion Kinase 1-Like

Ensembl ID : ENSSMAG00000005698
Gene Symbol: LOC118291845
2 Cross references
246 Possible Orthologues:

Folate Receptor Gamma

Ensembl ID : ENSSMAG00000019568
Gene Symbol: FOLR3
3 Cross references
436 Possible Orthologues:

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSSMAG00000004334
Gene Symbol: FSHR
3 Cross references
200 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSSMAG00000000878
Gene Symbol: FRK
3 Cross references
202 Possible Orthologues:

Galactosidase, Alpha

Ensembl ID : ENSSMAG00000012425
Gene Symbol: GLA
3 Cross references
196 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) B Receptor, 1a

Ensembl ID : ENSSMAG00000016587
Gene Symbol: GABBR1A
2 Cross references
197 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) B Receptor, 2

Ensembl ID : ENSSMAG00000012423
Gene Symbol: GABBR2
1 Cross references
208 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-2

Ensembl ID : ENSSMAG00000013178
Gene Symbol: LOC118319921
2 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-5-Like

Ensembl ID : ENSSMAG00000001026
Gene Symbol: LOC118309565
2 Cross references
202 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha1

Ensembl ID : ENSSMAG00000004920
Gene Symbol: GABRA1
3 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).